<DOC>
	<DOC>NCT02620163</DOC>
	<brief_summary>To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment</brief_summary>
	<brief_title>Efficacy &amp; Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Signed Informed Consent Men and women ≥ 19 years of age Essential hypertensive patients 1. If already taking antihypertensive drugs, mean sitting systolic blood pressure (MSSBP) must be 140 mmHg ≤ MSSBP &lt; 200 mmHg 2. If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (MSSBP) must be 160 mmHg ≤ MSSBP &lt; 200 mmHg Patients with known or suspected secondary hypertension Other exclusions applied</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>